zoledronic acid has been researched along with Musculoskeletal Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bardia, A; Blackford, AL; Connolly, RM; Fetting, JH; Hayes, DF; Henry, NL; Jeter, SC; Miller, RS; Nguyen, A; Quinlan, K; Rosner, GL; Santa-Maria, CA; Slater, S; Snyder, C; Stearns, V; Storniolo, AM; Wolff, AC; Zorzi, J | 1 |
| He, W; Liu, XA; Yang, T; Zhang, PL; Zhou, WB | 1 |
1 review(s) available for zoledronic acid and Musculoskeletal Diseases
| Article | Year |
|---|---|
Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis.
Topics: Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Musculoskeletal Diseases; Randomized Controlled Trials as Topic; Zoledronic Acid | 2011 |
1 trial(s) available for zoledronic acid and Musculoskeletal Diseases
| Article | Year |
|---|---|
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Middle Aged; Musculoskeletal Diseases; Odds Ratio; Proportional Hazards Models; Treatment Outcome; Zoledronic Acid | 2018 |